Live Breaking News & Updates on Harish seethamraju
Stay updated with breaking news from Harish seethamraju. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mount Sinai Names Scott Scheinin, MD, as Director for Lung Failure and Transplantation miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Mount Sinai Health System in New York City performed it's first double lung transplant on Iron Chef America and 9/11 volunteer, chef James Kelly of New York
Judge sides with Vancouver, Wash.-based CytoDyn against Portland-led activist shareholder group mounting proxy fight bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
About OneNews OneNews.PH is the online presence of OneNews, the all-news channel of Cignal TV and the synergy of the journalistic strengths of The Philippine STAR, philstar.com, TV5 Network Inc. and BusinessWorld under Mediaquest Holdings Inc. About Leronlimab (PRO 140) Leronlimab has been studied in 11 clinical trials involving more than 1,200 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients). Leronlimab is a viral-entry inhibitor in HIV/AIDS. It masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Nine clinical trials have demonstrated leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent with fewer side effects and less frequent dosing requirements than currently used daily drug therapies.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. CytoDyn’s Leronlimab Featured on OneNews in Philippines on May 9 CytoDyn Inc.May 7, 2021 GMT Drs. Pourhassan, Recknor, Seethamraju and Nicolas will appear in a one-hour segment beginning at 5:00 pm PT / 8:00 pm ET, Sunday, May 9 VANCOUVER, Washington, May 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today its drug candidate, leronlimab, will be featured in a one-hour news segment on Sunday, May 9, at 5:00 pm PT / 8:00 pm ET on OneNews in the Philippines. CytoDyn has been supplying leronlimab to the Philippines as a therapeutic treatment for critically ill COVID-19 patients under Compassionate Special Permits (CSPs) authorized by the Philippine FDA.
NA Proactive news snapshot: KWESST Micro Systems, Sassy Resources, Power REIT, Delta 9 Cannabis UPDATE … A glance at some of the day's highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive KWESST Micro Systems Inc (CVE:KWE) (OTCQB:KWEMF) announced plans to hold an investor update call at 2 pm ET on Tuesday, May 11. Executive Chairman David Luxton will describe the significance of the company's acquisition of Low Energy Cartridge (LEC) systems and the go-to-market strategy for the LEC, the world's first cartridge based non-lethal weapon system. Interested parties can email questions to investors@kwesst.com prior to or during the meeting. To dial in, call 647-374-4685 in Canada or 929-205-6099 in the US. "One priority for KWESST is to begin the commercialization of the LEC system with an accelerated plan in response to market interest and high growth across all segments of the non-lethal market. In this market, there a strong preference being expressed for a safer, cartridge-based system over traditional systems, such as taser, beanbag shotgun shells and rubber bullets, which can and do result in fatalities,” Luxton said.
NA Proactive news snapshot: KWESST Micro Systems, Sassy Resources, Power REIT, Delta 9 Cannabis UPDATE … A glance at some of the day's highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive KWESST Micro Systems Inc (CVE:KWE) (OTCQB:KWEMF) announced plans to hold an investor update call at 2 pm ET on Tuesday, May 11. Executive Chairman David Luxton will describe the significance of the company's acquisition of Low Energy Cartridge (LEC) systems and the go-to-market strategy for the LEC, the world's first cartridge based non-lethal weapon system. Interested parties can email questions to investors@KWESST.com prior to or during the meeting. To dial in, call 647-374-4685 in Canada or 929-205-6099 in the US. "One priority for KWESST is to begin the commercialization of the LEC system with an accelerated plan in response to market interest and high growth across all segments of the non-lethal market. In this market, there a strong preference being expressed for a safer, cartridge-based system over traditional systems, such as taser, beanbag shotgun shells and rubber bullets, which can and do result in fatalities,” Luxton said.
VANCOUVER, Washington, March 05, 2021 -- CytoDyn Inc. , a late-stage biotechnology company developing Vyrologix™ , a CCR5 antagonist with the potential for multiple therapeutic... | March 11, 2021